Effects of classic and newer antidepressants on the oxidation pathways of caffeine in rat liver. In vitro study

Polish Journal of Pharmacology

Volumn 55, Issue 6, 2003, Pages 1045-1053

  Daniel, Władysława A ^a   Kot, Marta ^a   Wójcikowski, Jacek ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Caffeine metabolism; Clomipramine; Desipramine; Mirtazapine; Nefazodone; Rat cytochrome P 450 activity; Sertraline

Indexed keywords

ANTIDEPRESSANT AGENT; CAFFEINE; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 1A2; DESIPRAMINE; ISOENZYME; MIRTAZAPINE; NEFAZODONE; PARAXANTHINE; SERTRALINE; THEOBROMINE; THEOPHYLLINE; URIC ACID DERIVATIVE;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; OXIDATION; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CAFFEINE; CLOMIPRAMINE; CYTOCHROME P-450 ENZYME SYSTEM; DESIPRAMINE; HYDROXYLATION; ISOENZYMES; MALE; MIANSERIN; MICROSOMES, LIVER; RATS; RATS, WISTAR; SERTRALINE; TRIAZOLES;

EID: 1642503076     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Berthou F., Flinois J.P., Ratanasavanh D., Beaune P., Riche C., Guillouzo A.: Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab. Disposition, 1991, 19, 561-567.
2. Berthou F., Goasduff T., Dreano Y., Menez J.-F.: Caffeine increases its own metabolism through cytochrome P4501A induction in rats. Life Sci., 1995, 57, 541-549.
3. Berthou F., Guillois B., Riche C., Dreano Y., Jacqz-Aigrain E., Beaune P.: Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica, 1992, 22, 671-680.
4. Chung W.G., Roch H.K., Kim H.M., Cha Y.N.: Involvement of CYP3A1, 2B, and 2E1 in C-8 hydroxylation and CYP1A2 and flavin-containing monooxygenase in N-demethylation of caffeine; identified by using inducer treated rat liver microsomes that are characterized with testosterone metabolic patterns. Chem.-Biol. Inter., 1998, 113, 1-14.
5. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E.: The effect of selective re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Brit. J. Clin. Pharmacol., 1992, 34, 262-265.
6. Daniel W., Adamus A., Melzacka M., Szymura J., Vetulani J.: Cerebral pharmacokinetics of imipramine after single and multiple dosages. Naunyn-Schmied. Arch. Pharmacol., 1981, 317, 209-213.
7. Daniel W.A., Haduch A., Wójcikowski J.: Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J. Pharm. Pharmacol., 2002, 54, 1545-1552.
8. Daniel W.A., Syrek M., Ryłko Z., Kot M.: Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol. J. Pharmacol., 2001, 53, 615-621.
9. Daniel W.A., Syrek M., Ryłko Z., Wójcikowski J.: Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes. Pol. J. Pharmacol., 2001, 53, 351-357.
10. Daniel W.A., Wójcikowski J.: The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol. Appl. Pharmacol., 1999, 158, 115-124.
11. Davis R., Whittington R., Bryson H.M.: Nefazodone. A review of its pharmacology, and clinical efficacy in the management of major depression. Drugs, 1997, 53, 608-636.
12. Eugster H.P., Probst M., Wurgler F.E., Sengstag C.: Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab. Disposition, 1993, 21, 43-49.
13. Fuhr U., Doehmer J., Battula N., Wolfel C., Kudla C., Keita Y., Staib A.H.: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol., 1992, 43, 225-235.
14. Fuller R.W., Hemrick-Luecke S.K., Littlefield E.S., Audia J.E.: Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Prog. Neuro-Psych. Biol. Psych., 1995, 19, 135-149.
15. Holm K.J., Markham A.: Mirtazapine. A review of its use in major depression. Drugs, 1999, 57, 607-631.
16. Kilban A.J., Silbart L.K., Manis M., Beitins O.Z., Weber W.W.: Human N-acetylation genotype determination with urinary caffeine metabolites. Clin. Pharmacol. Ther., 1990, 47, 470-477.
17. Morita K., Maeda Y., Masuda M., Kazusaka A., Imaoka S., Funae Y., Fujita S.: Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Biochem. Pharmacol., 1998, 55, 1405-1411.
18. Rostami-Hodjegan A., Nurminen S., Jackson P.R., Tucker G.T.: Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 1996, 6, 121-149.
19. Rotzinger S., Baker G.B.: Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. Eur. Neuropsychopharmacol., 2002, 12, 91-100.
20. Störmer E., von Moltke L.L., Shader R.I., Greenblatt D.J.: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6 and 3A4. Drug Metab. Disposition, 2000, 28, 1168-1175.
21. Tassaneeyakul W., Birkett D.J., McManus M.E., Tassaneeyakul W., Veronese M.E., Andersson T., Tukey R.H., Miners J.O.: Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol., 1994, 47, 1767-1776.
22. Weigmann H., Gerek S., Zeisig A., Muller M., Hartter S., Hiemke C.: Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from therapeutic drug monitoring service. Ther. Drug Monit., 2001, 23, 410-413.
23. Wójcikowski J., Daniel W.A.: Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol. J. Pharmacol., 2000, 52, 449-457.